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Abstract 
Background: The most common type of cancer is an adenocarcinoma of  the 
pancreas, 95% of all cancerous tumors is adenocarcinoma. Pancreatic 
adenocarcinoma is the 4
th
 leading cause of cancer death. 
The objective of this study is to assess serum bilirubin in relation to 
pancreatic cancer before and after treatment according to age and gender. 
The study was conducted in Radiation and Isotopes center Khartoum state 
during the period from December 2017 to September 2018.  
84 patients with pancreatic cancer were included in the study (50 males and 
34 females). Their ages range from 20 to 70 years. The normal range of  
total bilirubin (up to 1.2 mg/dl), direct bilirubin (up to 0.25mg/dl) and 
indirect bilirubin(up to 0.95mg/dl)  was used as a control for the cases. 
The study was a survey for 3 years ago. 
The serum values of total bilirubin (T.Bil) in primary stage before treatment, 
after surgery and after chemo-radio therapy were (9.56±1.48, 2.01±0.77, and 
1.48±0.49)mg/dl respectively. 
Direct bilirubin (D.Bil) values before treatment, after surgery and after 
chemo-radio therapy were (5.56±1.40, 0.80±0.60, and 0.45±,0.38)mg/dl 
respectively. 
Indirect bilirubin (ID.Bil) values before treatment, after surgery and after 
chemo-radio therapy were (3.96±1.26, 1.19±0.46 and1.02±0.37)mg/dl 
respectively. 
The results showed that the effective treatment that lower bilirubin level in 
the primary stage was chemo-radio therapy in all 3 years cases. 
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 Effect of chemo-radio therapy was highly significant difference (P≤0.000), 
(P≤0.007) respectively in (T.bil) and (D.bil) than surgery. But there was no 
significant difference between chemo-radio therapy and surgery in (ID.bil). 
The serum values of total bilirubin (T.Bil) in advanced stage before 
treatment, after chemo-radio therapy and after surgery were (14.16±2.40, 
2.70±1.42 and3.75±1.23)mg/dl respectively. 
Direct bilirubin (D.Bil) values before treatment, after chemo-radio therapy 
and after surgery were (9.42±1.99, 1.22±0.93and1.47±0.79)mg/dl 
respectively.  
Indirect bilirubin (ID.Bil) values before treatment, after chemo- radio 
therapy and after surgery were (4.52±1.86, 1.44±0.76and2.28±0.83)mg/dl 
respectively. 
The results showed that the effective treatment that lower bilirubin level in 
the advanced stage was surgery in all 3 years cases. 
 Effect of surgery was highly significant difference (P≤0.000) in (T.bil) and 
(ID.bil) than chemo-radio therapy. But there was no significant difference 
between surgery and chemo-radio therapy in (D.bil).  
The serum values of total bilirubin (T.Bil) in more advanced stage before 
treatment and after chemotherapy were (22.70±5.46 and 15.74±6.21)mg/dl 
respectively, direct bilirubin (D.Bil) values before treatment and after 
chemotherapy were (17.66±5.59 and 11.14±5.72)mg/dl respectively, and 
indirect bilirubin (ID.Bil) values before treatment and after chemotherapy 
were (4.90±2.42 and4.60±1.84)mg/dl respectively. 
The results showed that treatment with chemotherapy lower bilirubin level 
in more advanced stage in all 3 years cases. 
There was significant difference (P≤0.000) before and after treatment with 
chemo therapy in more advanced stage in (T.bil) and (D.bil). But there was 
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no significant difference before and after treatment with chemotherapy in 
(ID.bil). 
The results showed that there was no significant difference between serum 
values of bilirubin in pancreatic cancer patients before and after treatment 
according to age, gender and years in all studies.  
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المستخلص 
 
 ػثارِ  يُّ %59 )يرض خثٍس ٌُشأ فً انغذِ(اكصر الإَاع انًُرشرِ نًرض انثُكرٌاس ْٕ:انخهفٍح 
. ػٍ صرطاٌ انثُكرٌاس ٌٕجذ فً رأس انثُكرٌاس ْٕٔ انًضثة انراتغ يٍ أصثاب انٕفاج فً انؼانى
ٔفقا   انٓذف يٍ انذراصّ قٍاس يؼذل انًادِ انصفرأٌّ نًرٌط صرطاٌ انثُكرٌاس قثم ٔتؼذ انؼلاض
. نهؼًر ٔانجُش
 انى 7102انفررِ دٌضًثر فً اجرٌد انذراصّ فً يركز انخرطٕو نهؼلاض تالأشؼّ ٔانطة انُٕٔي 
 .8102صثرًثر 
صُّ 02ذررأح اػًارْى تٍٍ ال )ايراِ43رجلا ٔ05( انذراصّ ارتؼّ ٔشًإٌَ يرٌضا خذضًٍ
انًادِ انصفرأٌّ , )دصى/ يم2.1انى (انًؼذل انطثٍؼً نهًادِ انصفرأٌّ انكهٍّ . صُّ 07انً
 .)دصى/يم59.0انى(ٔانًادِ انصفرأٌّ انغٍر يثاشرِ )دصى/يم52.0انى (انًثاشرِ
 .اجرٌد انذراصّ نصلاز صُٕاخ صاتقّ
 فً انًرحهّ الأٔنى قثم انؼلاض ٔتؼذ انجراحّ ٔتؼذ ِ أٌ يؼذل انًادِ انصفرأٌّ انكهًِأظٓرخ انذراس
 ػهى  دصى/غىيم94.0±84.1 dna ,77.0±10.2 ,84.1±65.9((انؼلاض انكًٍأي الاشؼاػً كاٌ
.  انرٕانً
ٔيؼذل انًادِ انصفرأٌّ انًثاشرِ قثم انؼلاض ٔتؼذ انجراحّ ٔتؼذ انؼلاض انكًٍأي الاشؼاػً 
.   ػهى انرٕانًدصى/غىيم )83.0,±54.0 ,06.0±08.0,04.1±65.5(كاٌ
يؼذل انًادِ انصفرأٌّ انغٍر يثاشرِ قثم انؼلاض ٔتؼذ انجراحّ ٔتؼذ انؼلاض انكًٍأي الاشؼاػً 
.  ػهى انرٕانًدصى /يهغى)73.0±20.1 ,64,0±91.1,,62.1±69.3(كاٌ
 اٌ انؼلاض الأفضم نخفط َضثح انًادِ انصفرأٌّ كاٌ انؼلاض انكًٍأي الاشؼاػً ِأظٓرخ انذراس
.  نهًصاتٍٍفً انًرحهّ الأٔنٍّ فً كم انصلاز صُٕاخ
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ػهى  انرٕانً نهًادِ ≤P(000.0)),≤P700.0)كاٌ ذاشٍر انؼلاض انكًٍأي الاشؼاػً ػانً انًؼٌُّٕ 
ٔنكٍ لإٌجذ اخرلاف يؼُٕي تٍٍ انؼلاض الاشؼاػً . انصفرأٌّ انكهٍّ ٔانًثاشرِ اكصر يٍ انجراحّ
 .انكًٍأي ٔانجراحّ فً يؼذل انًادِ انصفرأٌّ انغٍر يثاشرِ
 
 انؼلاض انجراحّ ٔتؼذ  فً انًرحهّ انًرقذيّ  قثم انؼلاض ٔتؼذِكًا أٌ يؼذل انًادِ انصفرأٌّ انكهً
.  ػهى انرٕانًدصى/غىيم)32.1±57.3 dna 24.1±07.2 ,04.2±61.41(انكًٍأي الإشؼاػً كاَد
انؼلاض انكًٍأي الإشؼاػً  ٔتؼذ  انجراحّٔيؼذل انًادِ انصفرأٌّ انًثاشرِ قثم انؼلاض ٔتؼذ
.  ػهى انرٕانًدصى/غىيم)97.0±74.1dna 39.0±22.1 ,99.1±24.9(
 انؼلاض انكًٍأي الإشؼاػً  انجراحّٔيؼذل انًادِ انصفرأٌّ انغٍر يثاشرِ قثم انؼلاض ٔتؼذ
.  ػهى انرٕانًدصى/غىيم)38.0 ±82.2 dna 67.0±44.1 ,68.1±25.4(
 أٌ انؼلاض الأفضم نخفط انًادِ انصفرأٌّ فً انًرحهّ انًرقذيّ كاَد انجراحّ فً ِأظٓرخ انذراس
.  نهًصاتٍٍكم انصلاز صُٕاخ
 ػهى انًادِ انصفرأٌّ انكهٍّ ٔانغٍر يثاشرِ اكصر يٍ ≤P(000.0 (كاٌ ذاشٍر انجراحّ ػانً انًؼٌُّٕ
ٔنكُّ لإٌجذ اخرلاف يؼُٕي تٍٍ انجراحّ ٔانؼلاض الاشؼاػً انكًٍأي . انؼلاض الاشؼاػً انكًٍأي
 . ػهى يؼذل انًادِ انصفرأٌّ انًثاشرِ
 فً انًرحهّ انًرقذيّ جذا قثم انؼلاض  ِٔأٌضا أظٓرخ انذراصاخ أٌ يؼذل انًادِ انصفرأٌّ انكهً
ٔيؼذل انًادِ  ػهى انرٕانً دصى /غىيم)12.6±47.51 ,64.5±07.22( ٔتؼذ انؼلاض انكًٍأي كاٌ
 )95.5±41.11,95.5±66.71(انصفرأٌّ انًثاشرِ قثم انؼلاض ٔتؼذ انؼلاض انكًٍأي كاٌ
ٔيؼذل انًادِ انصفرأٌّ انغٍر يثاشرِ قثم انؼلاض ٔتؼذ انؼلاض انكًٍأي ػهى انرٕانً دصى /غىيم
.  ػهى انرٕانًدصى/غى يم)48.1±06.4 ,24.2±09.4(كاَد
 أٌ يؼذل انًادِ انصفرأٌّ فً انًرحهّ انًرقذيّ جذا اَخفط تؼذ انؼلاض انكًٍأي ِأظٓرخ انذراس
 . نهًصاتٍٍفً كم انصلاز صُٕاخ
 قثم ٔتؼذ انؼلاض انكًٍٍائً فً انًرحهّ انًرقذيّ جذا ػهى انًادِ ≤P(000.0(ُْاك ػلاقّ يؼٌُّٕ
ٔنكُّ لإٌجذ اخرلاف يؼُٕي تٍٍ قثم ٔتؼذ انؼلاض انكًٍٍائً ػهى انًادِ . انصفرأٌّ انكهٍّ ٔانًثاشرِ
 .انصفرأٌّ انغٍر يثاشرِ
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اَّ نٍش ُْاك ػلاقّ يؼٌُّٕ تٍٍ يؼذل انًادِ انصفرأٌّ نًرٌط صرطاٌ ِ أظٓرخ انذراس
  . انذراصاخ  فً كمٔانضُٕاخ تانجُش ٔانؼًرقثم ٔتؼذ انؼلاض  انثُكرٌاس 
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Chapter one 
1.1. Introduction: 
Definition of cancer: Cancers are a largefamily of diseases that involve 
abnormal cell growth with the potential to invade or spread to other parts of 
the body 
[1]
 
[2]
 .They form a subset of neoplasms. A neoplasm or tumor is a 
group of cells that have undergone unregulated growth and will often form a 
mass or lump, but may be distributed diffusely
[3]
 
[4]
.All tumor cells show the 
six hallmarks of cancer. These characteristics are required to produce a 
malignant tumor. They include: 
[5]
 
 Cell growth and division absent the proper signals 
 Continuous growth and division even given contrary signals 
 Avoidance of programmed cell death 
 Limitless number of cell divisions 
 Promoting blood vessel construction 
 Invasion of tissue and formation of metastases 
[6]
. The progression 
from normal cells to cells that can form a detectable mass to outright 
cancer involves multiple steps known as malignant progression.
[5]
 
[6]
 . 
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 Pancreas: Pancreas is an endocrine and digestive organ that, in humans, 
lies in the upper left part of the abdomen. It is found behind the stomach.
[7]
 
The pancreas is about 15 cm (6 in) long.
[8]
                                          
Anatomically, the pancreas is divided into the head of pancreas, the neck of 
pancreas, the body of pancreas, and the tail of pancreas.
[9]
 The head is 
surrounded by the duodenum in its concavity. The head surrounds two blood 
vessels, the superior mesenteric artery and vein. From the back of the head 
emerges a small unicinate process, which extends to the back of the superior 
mesenteric vein and ends at the superior mesenteric artery.
[10]
 The neck is 
about 2.5 cm (1 in) long and lies between the head and the body and in front 
of the superior mesenteric artery and vein. Its front upper surface supports 
the pylorus (the base) of the stomach. The body is the largest part of the 
pancreas and lies behind the pylorus, at the same level as the transpyloric 
plane.
[11]
 The tail ends by abutting the spleen.                                                    
The pancreas is a secretory structure with an internal hormonal role 
(endocrine) and an external digestive role (exocrine). The endocrine part is 
composed of hormonal tissue distributed along the pancreas in discrete units 
called islets of Langerhans.
[9]
 Islets of Langerhans have a well-established 
structure and form density routes through the exocrine tissue.
[9]
 The exocrine 
part has two main ducts, the main pancreatic duct and the accessory 
pancreatic duct. These drain enzymes through the ampulla of Vater into the 
duodenum.
[12]
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Pancreatic cancer: pancreatic cancer arises when cells in the pancreas, a 
glandular organ behind the stomach, begins to multiply out of control and 
form a mass. These cancerous cells have the ability to invade other parts of 
the body.
[13]
 There are a number of types of pancreatic cancer.
[10]
 The most 
common, pancreatic adenocarcinoma, accounts for about 85% of cases, and 
the term "pancreatic cancer" is sometimes used to refer only to that type.
[6]
 
These adenocarcinomas start within the part of the pancreas which makes 
digestive enzymes 
[10]
. One to two percent of cases of pancreatic cancer are 
neuroendocrine tumors, which arise from the hormone-producing cells of the 
pancreas.
[10]
 These are generally less aggressive than pancreatic 
adenocarcinoma.
[10]
                                                                                                                
Most pancreatic cancers are exocrine cancers, the head of pancreas located 
close to the common bile duct and duodenum (small bowel), so tumors 
located in the pancreas may grow and block these structures. Bile duct 
blockage can lead to jaundice in 70-85% of patients with tumors in the head 
of the pancreas 
[14]
.                                                                                           
Jaundice it is a clinical condition characterized by yellow discoloration of 
skin, sclera and mucus membrane. It is due to increase plasma bilirubin 
above 3 mg/dl. At this level, bilirubin diffuses into tissues giving yellow 
color.                                                                                                        
Bilirubin is a yellow compound that occurs in the normal catabolic pathway 
that breaks down heme in vertebrates 
[15]
. 
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Formation of Bilirubin: 
The heme ring is catabolizied by the microsomal heme oxygenase enzymes 
of the endoplasmic reticulum cells. 
In this reaction (which needs, heme oxygenase enzyme, O2 and NADPH), 
iron (fe
++
) is removed for re-use. The remaining of heme ring is cleaved 
between pyrrole rings number I and II to form biliverdin (green pigment) 
and carbon monoxide (Co). 
Biliverdin is then reduced into bilirubin (golden yellow) in a reaction 
requires biliverdin reductase enzyme [16]. 
Transport of bilirubin in the plasma: 
Bilirubin is non polar, and is insoluble in plasma. Therefore it binds 
noncovalentling bonds to plasma albumin. This form is called: unconjugated 
or indirect bilirubin
[16]
. 
Uptake of bilirubin by the liver: 
Bilirubin dissociates from the carrier albumin molecule and enters 
hepatocytes. 
Bilirubin is conjugated with one or two molecules of glucuronic acid (the 
acid form of glucose) to form bilirubin monoglucuronide and bilirubin 
diglucuronide. This reaction needs UDP-glucuronyltransferase enzyme: 
Bilirubin +UDP –Glucuronate -----------transferase-------- bilirubin 
glucuronide (s) +UDP [16]. 
Secretion of bilirubin into bile: 
Bilirubin diglucuronide is actively transported against concentration 
gradient into the bile canalciuli and then into the bile [16]. 
Formation of urobilin in the intestine: 
Intestinal bacteria acts on bilirubin diglucuronide leading to: 
removal of glucuronides (by B- glucuroidase enzymes). 
  5 
 
Reduction of bilirubin to colorless compounds called: 
urobilinogens(=stercobilinogen)[16]. 
A small fraction of urobilinogens are reabsorbed from intestine to the liver 
again and re-excreted in the bile, forming the entrohepatic urobilinogens 
cycle [16]. 
Excretion of urobilinogens in stool and urine: 
Most of the colorless urobilinogens are oxidized to the colored urobilin 
(stercobilin), which excreted in the stool giving its brown color. 
Part of urobilinogens are reabsorbed to the liver, then to the blood to be 
excreted by the kidney in urine and coverted into urobilin. 
Urobilin – together with urochrome give the characteristic yellow color of 
urine [16]. 
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1.2. Justification 
 Pancreatic cancer associated with jaundice is the fourth leading cause of 
cancer death in the world. 
 Around 70-85% of patients with tumor in the head of pancreas cause 
obstructive jaundice (Diane 2012).  
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1. 3. Objective 
1.3.1. General objective: 
To assess the level of serum bilirubin in pancreatic cancer patients attended 
at Radiation and Isotopes Center Khartoum. 
1.3.2. Specific objective: 
 To estimate the total serum bilirubin (T.Bil) concentration (mg/dl) 
before and after treatment according to age and gender. 
 To estimate the direct serum bilirubin (D.Bi) concentration (mg/dl) 
before and after treatment according to age and gender. 
 To estimate the indirect serum bilirubin (ID.Bil) concentration (mg/dl) 
before and after treatment according to age and gender. 
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Chapter two 
Literature review 
2.1. Types of pancreatic cancer:                                                      
2.1.1. Exocrine cancer: Nearly all these start in the ducts of the 
pancreas, as pancreatic ductal adenocarcinoma (PDAC).
[19]
 This cancer 
originates in the ducts that carry secretions (such as enzymes and 
bicarbonate) away from the pancreas. About 60–70% of adenocarcinomas 
occur in the head of the pancreas 
[9]
.The pancreas makes pancreatic juices. 
These pancreatic juices are produced by the exocrine glands and contain 
enzymes that help digest food. When food enters the stomach, the pancreas 
releases these enzymes into a system of ducts. The main pancreatic duct 
joins the common bile duct, which originates from the liver and gallbladder. 
The common bile duct carries bile, a fluid that helps in digestion of fat, and 
it empties into the duodenum, the first part of the small intestine 
[20]
. 
2.1.2. Neuroendocrine: The small minority of tumors that arise 
elsewhere in the pancreas are mainly pancreatic neuroendocrine tumors 
(PanNETs).
[21]
Neuroendocrine tumors (NETs) are a diverse group of benign 
or malignant tumors that arise from the body's neuroendocrine cells, which 
are responsible for integrating the nervous and endocrine systems.  
2.2. Signs and symptoms: 
Pain in the upper abdomen or back, often spreading from around the 
stomach to the back 
[23]
.  
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Jaundice, a yellow tint to the whites of the eyes or skin, with or without  pain 
,and possibly in combination with darkened urine. This results when a 
cancer in the head of the pancreas obstructs the common bile duct as it runs 
through the pancreas 
[24]
 .Weight loss, either from loss of appetite, or loss of 
exocrine function 
[25]
. The tumor may compress neighboring organs, 
disrupting digestive processes and making it difficult for the stomach to 
empty, which may cause nauseaand a feeling of fullness 
[25]
.Constipation is 
common
[26]
. At least 50% of people with pancreatic adenocarcinoma have 
diabetes at the time of diagnosis.
[9]
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2.3. Risk factors:                                                                          
The strongest risk factor for pancreatic cancer is increasing age. In the USA, 
the median age at diagnosis is 72 
[9] [27] [25]
. Risk is low (10.4 per 100,000) in 
those aged 50–54, increasing sharply to 73.5 per 100,000 in those aged 75–
79 
[27 ] [12] [15]
and continuing to increase in older individuals. Gender: risk is 
higher in men than in women 
[28] [20] [29]
. In 2015, pancreatic cancers of all 
types resulted in 411,600 deaths globally 
[30]. The disease is more common in 
men than women 
[10] [9] .                                          
2.4.Pathophysiology:                                                                   
Exocrine cancers are thought to arise from several types of   
precancerouslesions within the pancreas. But these lesions do not always 
progress to cancer, and the increased numbers detected as a by-product of 
the increasing use of CT scans for other reasons are not all treated.
[27]
 Apart 
from pancreatic serous cystadenomas (SCNs), which are almost always 
benign, four types of precancerous lesion are recognized. The first is 
pancreatic intraepithelial neoplasia. These lesions are microscopic 
abnormalities in the pancreas and are often found in autopsies of people with 
no diagnosed cancer. These lesions may progress from low to high grade and 
then to a tumor. More than 90% of cases at all grades carry a faulty KRAS 
gene, while in grades 2 and 3 damage to three further genes – CDKN2A 
(p16), p53 and SMAD4 – are increasingly often found.[9] A second type are 
the intraductal papillary mucinous neoplasms (IPMNs). These are 
macroscopic lesions, which are found in about 2% of all adults. This rate 
rises to ~10% by age 70. These lesions have about a 25% risk of developing 
into invasive cancer. They may have KRAS gene mutations (~40–65% of 
cases) and in the GNAS Gs alpha subunit and RNF43, affecting the Wnt 
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signaling pathway [9]. Even if removed surgically, there remains a 
considerably increased risk of pancreatic cancer developing subsequently.
[27]
 
The third type, pancreatic mucinous cystic neoplasms (MCNs) mainly occur 
in women, and may remain benign or progress to cancer.
[33]
 If these lesions 
become large, cause symptoms, or have suspicious features, they can usually 
be successfully removed by surgery 
[27]. A fourth type of cancer that arises in 
the pancreas is the intraductaltubulopapillary neoplasm. This type was 
recognised by the WHO in 2010 and constitutes about 1–3% of all 
pancreatic neoplasms. Mean age at diagnosis is 61 years (range 35–78 
years). About 50% of these lesions become invasive. Diagnosis depends on 
histology as these lesions are very difficult to differentiate from other lesions 
on either clinical or radiological grounds.
[34]
 Invasive cancer: the genetic 
events found in ductal adenocarcinoma have been well characterized , and 
complete exome sequencing has been done for the common types of tumor. 
Four genes have each been found to be mutated in the majority of 
adenocarcinomas: KRAS (in 95% of cases), CDKN2A (also in 95%), TP53 
(75%), and SMAD4 (55%). The last of these are especially associated with a 
poor prognosis.
[27] SWI/SNF mutations/deletions occur in about 10–15% of 
the adenocarcinomas.
[9]
 The genetic alterations in several other types of 
pancreatic cancer and precancerous lesions have also been researched 
[27].Transcriptomics analyses and mRNA sequencing for the common forms 
of pancreatic cancer have found that 75% of human genes are expressed in 
the tumors, with some 200 genes more specifically expressed in pancreatic 
cancer as compared to other tumor types.
[35]
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2.5. Staging: 
Exocrine cancers: Pancreatic cancer is usually staged following a CT 
scan.
[36]
 The most widely used cancer staging system for pancreatic cancer is 
the one formulated by the American Joint Committee on Cancer (AJCC) 
together with the Union for International Cancer Control (UICC). The 
AJCC-UICC staging system designates four main overall stages, ranging 
from early to advanced disease, based on TNM classification of tumor size, 
spread to lymph nodes, and metastasis.
[37] 
To help decide treatment, the tumors are also divided into three broader 
categories based on whether surgical removal seems possible: in this way, 
tumors are judged to be "resectable", "borderline resectable", or 
"unresectable".
[38]
 When the disease is still in an early stage (AJCC-UICC 
stages I and II), without spread to large blood vessels or distant organs such 
as the liver or lungs, surgical resection of the tumor can normally be 
performed, if the patient is willing to undergo this major operation and is 
thought to be sufficiently fit.
[25]
 The AJCC-UICC staging system allows 
distinction between stage III tumors that are judged to be "borderline 
resectable" (where surgery is technically feasible because the celiac axis and 
superior mesenteric artery are still free) and those that are "unresectable" 
(due to more locally advanced disease); in terms of the more detailed TNM 
classification, these two groups correspond to T3 and T4 respectively.
[27]
 
Locally advanced adenocarcinomas have spread into neighboring organs, 
which may be any of the following (in roughly decreasing order of 
frequency): the duodenum, stomach, transverse colon, spleen, adrenal gland, 
or kidney. Very often they also spread to the important blood or lymphatic 
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vessels and nerves that run close to the pancreas, making surgery far more 
difficult. Typical sites for metastatic spread (stage IV disease) are the liver, 
peritoneal cavity and lungs, all of which occur in 50% or more of fully 
advanced cases.
[40]
 
2.6. Management: 
2.6.1. Surgery: 
There are some studies indicating that Since pancreatic cancer was first 
described by Montiere in 1836, the apparent global incidence of the disease 
has increased three or four times
[41-42]
 . In the United States in 1990, about 
27,000 new cases will be diagnosed. Approximately the same number of 
patients will die of the disease during that period 
[43] [44]
. Only 10% to 15% of 
patients with pancreatic cancer are suitable for possible curative resection 
[45] 
[46]
.  The symptoms that most commonly require relief in patients with 
pancreatic cancer are jaundice, gastric outlet obstruction, and pain. Opinions 
vary concerning the best approach to the treatment of these problems, as 
well as their efficacy. To shed some light on these issues, They reviewed 
retrospectively a 16-year experience (1973 to 1988) with the palliation of 
pancreatic cancer at the University of California, Los Angeles 
(UCLA)
.
Pancreatic cancer is considered resectable if the tumor appears to be 
localized to the pancreas without invasion into important surrounding 
structures such as the mesenteric blood vessels (that supply blood to the 
intestines) which are located adjacent to the head portion of the pancreas. 
Furthermore there should be no evidence of metastatic spread to liver or 
lining of the intestines surgical removal of the tumor is a treatment of choice 
for patients with resectable pancreatic cancer. The surgery involves removal 
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of all tumors that is visible at the time of surgery 
[43]
.
 
For cancers involving 
the head of the pancreas, the Whipple procedure is the most commonly 
attempted curative surgical treatment. This is a major operation which 
involves removing the pancreatic head and the curve of the duodenum 
together ("pancreato-duodenectomy"), making a bypass for food from the 
stomach to the jejunum ("gastro-jejunostomy") and attaching a loop of 
jejunum to the cystic duct to drain bile ("cholecysto-jejunostomy"). It can be 
performed only if the person is likely to survive major surgery and if the 
cancer is localized without invading local structures or metastasizing 
[9] [79] 
[7]
.
 
A whipple operation involves removal of the head (first part) of the pancreas 
and usually about 20% of the pancreas is removed. The bottom half of the 
bile duct and the first portion of the intestine called the duodenum is also 
removed and the stomach is preserved. This procedure called the pylorus 
preserving whippleoperation .occasionally part of stomach may be removed 
and this operation is called the standard operation 
[47]
.This operation will 
lowering the bilirubin concentration to normal range. Although curative 
surgery no longer entails the very high death rates that occurred until the 
1980s, a high proportion of people (about 30–45%) still have to be treated 
for a post-operative sickness that is not caused by the cancer itself. The most 
common complication of surgery is difficulty in emptying the stomach.
[27] [79]
 
Certain more limited surgical procedures may also be used to ease 
symptoms: for instance, if the cancer is invading or compressing the 
duodenum or colon. In such cases, bypass surgery might overcome the 
obstruction and improve quality of life but is not intended as a cure.
[25]
 
Obstructive jaundice is the most common symptom in patients with 
advanced cancer (borderline resectable) of the pancreatic head. For patients 
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with a resectable tumor who have no radiologic evidence of metastasis, 
surgical resection is the only option for cure 
[48] [49]
 Since surgery in patients 
with jaundice is thought to increase the risk of postoperative complications, 
preoperative biliary drainage was introduced to improve the postoperative 
outcome 
[50]
. In several experimental studies and retrospective case series, 
preoperative biliary drainage reduced morbidity and mortality after surgery 
[50] [51]
.patients with pancreatic cancers located in the head of the gland 
present with biliary obstruction. A decision regarding preoperative biliary 
decompression must then be made, and a number of different bilirubin 
threshold levels and approaches have been described 
[52]
.Reported results 
from a multicenter, randomized trial of 202 patients with elevated bilirubin 
levels (2.3 to 14.6 mg/dl) who were assigned to undergo immediate surgery 
or preoperative endoscopic biliary drainage. The authors found that the 
biliary drainage group had significantly higher endoscopic and stent-related 
complications (P< 0.001) without an improvement in the rate of 
perioperative complications (P = 0.14). Similarly.from Memorial Hospital in 
New York also found that the preoperative endoscopic placement of biliary 
stents resulted in a two-fold increase in postpancreatectomy infectious 
complications. These two studies suggest that preoperative biliary stenting 
should be used selectively in patients with biliary obstruction prior to 
pancreaticoduodenectomy. They have taken a similar approach and have 
arranged for patients with bilirubin levels of greater than 25 mg/dl or those 
with evidence of synthetic liver dysfunction, as assessed by an elevated 
serum INR level, to undergo preoperative stenting. Surgery is delayed until 
the bilirubin level is less than 20 mg/dl and the INR is within a normal range 
[53] [80]
. 
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Around 60-70% of pancreatic cancers are located in the pancreatic head 
[53]
, 
leading to hyperbilirubinaemia caused by obstruction of the central bile duct 
in 70-80% of these patients 
[54]
. Biliary obstruction and the resulting 
hyperbilirubinaemia usually complicate the management of patients by 
increasing the risk of cholangitis and causing frequent hospitalizations 
[55]
; 
hyperbilirubinaemia has been associated with shorter overall survival in 
patients with pancreatic cancer 
[56] [57]
. Biliary decompression in patients with 
obstructive hyperbilirubinaemia is commonly performed using endoscopic 
stent placement
[58]
, which not only reduces morbidity but also facilitates 
treatment with chemotherapy by allowing total bilirubin levels to drop to ≤ 
1.5-2 times the upper limit of normal (≤ 1.5-2 × ULN). Other possible 
causes of hyperbilirubinaemia in patients with pancreatic cancer are 
obstruction of the peripheral intrahepatic bile ducts due to tumour 
metastases, without major impairment of other aspects of liver function, or 
massive infiltration of the liver by tumour metastases resulting in non-
cirrhotic liver failure
[59][79][77]
. The rationale for biliary decompression in 
patients with  resectable pancreatic cancer and obstructive cholestasis is the 
normalisation of the bilirubin levels to allow palliative chemotherapy, and 
the prevention of other adverse outcomes such as cholangitis and frequent 
hospitalizations 
[55]
According to the current German, European and 
American treatment guidelines, stent placement via endoscopic retrograde 
cholangiopancreatography (ERCP) is the preferred method for biliary 
decompression in these patients
[54][58][60]
.In case ERCP is not possible, 
percutaneous transhepatic biliary drainage (PTCD) is recommended
[54] [58] 
[60].
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.Endoscopic ultrasound-guided transoesophageal or transduodenal biliary 
drainage represents a treatment alternative in selected patients not suitable 
for conventional ERCP and PTCD 
[61] [62]
. 
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2.6.2. Chemotherapy:                                                                
After surgery, neo adjuvant chemotherapy  with gemcitabine or 5-FU and 
radition  has been effective than surgery in lowering bilirubin levelin 
pancreas cancer in attempt to improve out come  and can be offered if the 
person is sufficiently fit for those with resectable tumors
[63] [64] [65 ][72] [74]
 , 
Before surgery , neo adjuvant chemotherapy or chemo-radiotherapy may be 
used in cases that are considered to be "borderline resectable" in order to 
reduce the cancer to a level where surgery could be beneficial ,the surgery 
more effective in this cases than chemo-radio therapy
[27]
 
[7]  [75]
, but in other 
hands the chemo-radio therapy is more effective in lowering bilirubin level 
to normal range
[73] [72] [75]
 . In other cases neoadjuvant therapy remains 
controversial, because it delays surgery. After a recovery period of one to 
two months 
[7]
 
[67]
. In people not suitable unresectable for curative surgery, 
chemotherapy may be used to extend life or improve its quality on 
hyperbilirubineama [27] [76] [78]. Gemcitabine was approved by the United 
States Food and Drug Administration (FDA) in 1997, after a clinical trial 
reported improvements in quality of life and a 5-week improvement in 
median survival duration in people with advanced pancreatic cancer
[68]
 .This 
was the first chemotherapy drug approved by the FDA primarily for a 
nonsurvival clinical trial endpoint.
[69]
 Chemotherapy using gemcitabine 
alone was the standard for about a decade, as a number of trials testing it in 
combination with other drugs failed to demonstrate significantly better 
outcomes. However, the combination of gemcitabine with erlotinib was 
found to increase survival modestly, and erlotinib was licensed by the FDA 
for use in pancreatic cancer in 2005
[70]
. 
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The FOLFIRINOXchemotherap regimen using four drugs was found more 
effective than gemcitabine, but with substantial side effects, and is thus only 
suitable for people with good performance status. This is also true of 
protein-bound paclitaxel (nab-paclitaxel), which was licensed by the FDA in 
2013 for use with gemcitabine in pancreas cancer 
[71]
. By the end of 2013, 
both FOLFIRINOX and nab-paclitaxel with gemcitabine were regarded as 
good choices for those able to tolerate the side-effects, and gemcitabine 
remained an effective option for those who were not. A head-to-head trial 
between the two new options is awaited, and trials investigating other 
variations continue. However, the changes of the last few years have only 
increased survival times by a few months.
[68]
 Clinical trials are often 
conducted for novel adjuvant therapies 
[7]
. 
2.6.3. Radiotherapy: 
The role of radiotherapy as an auxiliary (adjuvant) treatment after potentially 
curative surgery has been controversial since the 1980
[27]
. Radiotherapy may 
form part of treatment to attempt to shrink a tumor to a resectable state, but 
its use on unresectable tumors remains controversial as there are conflicting 
results from clinical trials. The preliminary results of one trial, presented in 
2013, "markedly reduced enthusiasm" for its use on locally advanced tumors 
, concurrent external-beam radiotherapy delivered in daily fractions over a 
six week period to total dose of approximately 5000 rads 
[9]
. 
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Chapter three 
Material and Methods 
3. Material 
3.1. Study design: 
Retrospective prospective study was done in pancreatic cancer patients. 
3.2. Study area and period: 
This study was conducted in Radiation and Isotopes Centre Khartoum 
during the period from December 2017 to September2018. 
3.3. Study subjects: 
 Pancreatic cancer patients who have the disease at any age and gender. 
3.4. Sample size: 
 84 Pancreatic cancer patients before treatment (control group) and    
pancreatic cancer patients after treatment with  surgery  and chemotherapy 
or radiation in this study( test group) . 
3.5. Exclusion criteria: 
 Any patients with one of the  following conditions was excluded: 
 Other type of cancer. 
 Gall stones. 
3.6. Ethical consideration: 
 Written consent was obtained from Ethical Committee- Ministry of 
Health_ statewide of Khartoum.  
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3.7. Data collection and clinical assessment: 
Data were collected from records survey for 3 years ago. 
3.8. Biochemical measurements: 
Serum samples were analyzed for total bilirubin (T.BIL) and direct bilirubin 
(D.BIL) by photometric (instrument limited model BS-200 Germany) using 
commercial kits (Mindary chemical, china). 
3.8.1. Estimation of total bilirubin: 
3.8.1.1. Principle of the method: 
By the action of vanadic acid ion at PH 3.0, bilirubin is oxidized to 
dehydrobilirubin, and the absorbency decreases at 450 nm is directly 
proportional to the concentration of total bilirubin. 
3.8.1.2. Reagents: 
 R1 Citrate buffer surfactant, 100mmol/L <1%. 
 R2 phosphate buffer vanadiate 10mmol/L, 4mmol/L. 
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3.8.1.3. Method: 
Into a measuring cuvette 2800µl of working reagent ( 1) were mixed with 
100 µl of sample , and incubated for 3 minutes at 37 c
o
 then700 µl of  
reagent (2)  were mixed thoroughly then incubated at 37c
o
 for 5 minutes and 
then read the absorbance: 
(T.BIL)=Absorbance of sample- Absorbance of blank 
A= {∆ A sample} – {∆ A blank} 
3.8.2. Estimation of direct bilirubin: 
3.8.2.1. Principle of method: 
By the action of inhibitor and vandic acid ion at PH 3.0, direct bilirubin is 
specially oxidized to dehydrobilirubin, and the absorbency decreases at 450 
nm is directly proportional to the concentration of direct bilirubin. 
3.8.2.2. Reagents: 
 R1 Tartrate buffer 100mmol/L. 
 R2 Phosphate buffer vanadiate 10mmol/L, 4mmol/L. 
3.8.2.3. Method: 
Into a measuring cuvette 2800 µl of working reagent(1) were mixed with    
100 µl of sample, and incubated for 3 minutes at 37 c
o
 then700 µl reagent (2) 
were mixed thoroughly and incubated at 37c
o
 for 5 minutes and then read the 
absorbance : 
(D.BIL)=Absorbance of sample- Absorbance of blank 
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A={∆ A sample} – {∆ A blank} 
3.8.3. Estimation of indirect bilirubin: 
Was measured from the following equation : 
(ID.BIL)=(T-BIL) - (D-BIL) 
3.9. Data analysis: 
Data were managed and analyzed using statistical package for the social 
sciences (SPSS) program. 
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Chapter four 
4. Results  
 
Primary stage:  
Table (1) :Relationship between total bilirubin level before treatment, after 
surgery and chemo- radio therapy in primary stage of pancreatic cancer. 
 
 Mean±SD 
Mg/dl 
P-value 
A 9.56±1.48 0.000 
B 2.01±0.77 
A 9.56±1.48 0.000 
C 1.48±0.49 
B 2.01±0.77 0.000 
C 1.48±0.49 
A: bilirubin level before treatment 
B: bilirubin level after surgery 
C: bilirubin level after chemo_radio therapy 
 
Mg/dl  
` 
Fig (1): Relationship between total bilirubin level before treatment, after 
surgery and chemo- radio therapy in primary stage of pancreatic cancer 
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Results presented in table and fig (1) indicated that there was significant 
difference (P≤0.000) between total bilirubin level before treatment, after 
surgery and chemo-radiotherapy. Before treatment total bilirubin level was 
9.56 mg/dl , after surgery was 2.01 mg/dl and after chemo radio therapy was 
1.48 mg/dl. Also the results showed that there was significant difference 
(P≤0.000) between total bilirubin level after surgery and chemo-
radiotherapy. 
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Table (2): Relationship between direct bilirubin level before treatment, after 
surgery and chemo- radio therapy in primary stage of pancreatic cancer 
 
 Mean±SD 
Mg/dl 
P-value 
A 5.56±1.40 0.000 
B 0.80±0.60 
A 5.56±1.40 0.000 
C 0.45±0.38 
B 0.80±0.60 0.007 
C 0.45±0.38 
 
mg/dl  
 
Fig (2): Relationship between direct bilirubin level before treatment, after 
surgery and chemo- radio therapy in primary stage of pancreatic cancer 
 
Results presented in table and fig (2) indicated that there was significant 
difference (P≤0.000) between direct bilirubin level before treatment, after 
surgery and after chemo-radiotherapy. Before treatment direct bilirubin level 
was 5.56 mg/dl after surgery was 0.80 mg/dl and after chemo-radio therapy 
was 0.45 mg/dl .The results showed that there was significant difference 
(P≤0.007) between direct bilirubin levels after surgery and chemo-radio 
therapy.  
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Table (3): Relationship between indirect bilirubin level before treatment, 
after surgery and chemo- radio therapy in primary stage of pancreatic cancer 
 
 
 
 
 
 
 
 
 
mg/dl 
 
Fig (3): Relationship between indirect bilirubin level before treatment, after 
surgery and chemo- radio therapy in primary stage of pancreatic cancer 
 
Results presented in table and fig (3) indicated that there was significant 
difference (P≤0.000) between indirect bilirubin level before treatment, after 
surgery and chemo- radio therapy .Before treatment indirect bilirubin was 
3.96mg/dl after surgery was 1.19mg/dl and after chemo-radio therapy was 
1.02mg/dl. The results showed that there was no significant difference 
between indirect bilirubin level after surgery and chemo-radio therapy.  
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 Mean±SD  
Mg/dl 
P-value 
A 3.96±1.26 0.000 
B 1.19±0.46 
A 3.96±1.26 0.000 
C 1.02± 0.37 
B 1.19±0.46 0.118 
C 1.02± 0.37 
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Advance stage: 
Table (4): Relationship between total bilirubin level before treatment, after 
surgery and after chemo-radio therapy in advance stage of pancreatic cancer 
 
 
 
 
 
 
 
 
 
 mg/dl 
 
Fig (4) :Relationship between total bilirubin level  before treatment, after 
surgery and after chemo-radio therapy in advance stage of pancreatic cancer 
 
Results presented in table and fig (4) indicated that there was significant 
difference (P<0.000) between total bilirubin level before treatment, after 
surgery and chemo-radio therapy. Before treatment total bilirubin level was 
14.16 mg/dl after surgery was 2.70 mg/dl and after chemo-radio therapy was 
3.75 mg/dl. The results showed that there was significant difference 
(P≤0.000) between total bilirubin level after surgery and chemo-radio 
therapy. 
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 Mean±SD 
Mg/dl 
P-value 
A 14.16±2.40 0.000 
B 2.70±1.42 
A 14.16±2.40 0.000 
C 3.75±1.230 
B 2.70±1.42 0.000 
C 3.75±1.23 
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Table (5): Relationship between direct bilirubin level before treatment, after 
surgery and after chemo-radio therapy in advance stage of pancreatic cancer 
 
 
Mean±SD 
Mg/dl 
P-value 
A 9.42±1.99 0.000 
B 1.22±0.93 
A 9.42±1.99 0,000 
C 1.47±0.79 
B 1.22±0.93 0.141 
C 1.47±0.79 
 
mg/dl 
Fig (5): Relationship between direct bilirubin level before treatment, after 
surgery and after chemo-radio therapy in advance stage of pancreatic cancer 
 
Results presented in table and fig (5) indicated that there was significant 
difference (P≤0.000) between direct bilirubin level before treatment and 
after surgery and chemo-radio therapy. Before treatment direct bilirubin 
level was 9.42 mg/dl, after surgery was 1.22 mg/dl and after chemo-radio 
therapy was 1.47 mg/dl. The results showed that there was no significant 
difference between direct bilirubin level after surgery and chemo-radio 
therapy. 
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Table (6): Relationship between indirect bilirubin level before treatment, 
after surgery and after chemo-radio therapy in advance stage of pancreatic 
cancer 
 
 Mean±SD 
Mg/dl 
P-value 
A 4.52±1.86 0.000 
B 1.44±0.76 
A 4.52±1.86 0.000 
C 2.28±0.83 
B 1.44±0.76 0.000 
C 2.28±0.83 
 
mg/dl 
  
Fig (6): Relationship between indirect bilirubin level before treatment, after 
surgery and after chemo-radio therapy in advance stage of pancreatic cancer 
 
Results presented in table and fig (6) indicated that there was significant 
difference (P<0.000) between indirect level before treatment, after surgery 
and after chemo-radio therapy. Before treatment indirect bilirubin was 4.52 
mg/dl after surgery was 1.44 mg/dl and after chemo-radio therapy was 2.28 
mg/dl.  The results showed that there was significant difference (P≤0.000) 
between indirect bilirubin level after surgery and chemo-radio therapy. 
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More advance: 
Table (7): Relationship between bilirubin level before treatment and after 
chemotherapy in more advance stage of pancreatic cancer 
 Mean±SD 
Mg/dl 
P-value 
A 22.70±5.46 0.000 
D 15.74±6.21 
A* 17.66±5.59 0.000 
D* 11.14±5.72 
A** 4.90±2.42 0.614 
D** 4.60±1.84 
A=Total bilirubin before treatment 
D=Total bilirubin after chemotherapy 
A*=Direct bilirubin before treatment 
D*= Direct bilirubin after chemotherapy 
A**=Indirect bilirubin before treatment 
D**= Indirect bilirubin after chemotherapy 
 
Mg/dl  
Fig (7): Relationship between bilirubin level before treatment and after 
chemotherapy in more advance of pancreatic cancer 
 
Results presented in table and fig (7)indicated that there was significant 
difference (P<0.000) between total bilirubin level before treatment and after 
chemo therapy the total bilirubin level before treatment was 22.70 mg/dl and 
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after  chemo therapy was 15.74 mg/dl, there  was significant 
difference(P<0.000) between direct bilirubin level before treatment and after 
chemo therapy the direct bilirubin before treatment was 17.66 mg/dl and 
after chemotherapy was 11.14 mg/dl,  and there was  no significant 
difference between indirect bilirubin level before  treatment and after chemo 
therapy ,indirect bilirubin level before treatment was (4.9) mg/dl and after 
chemo therapy was (4.6)mg/dl. 
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Chapter five 
5.1. Discussion: 
Pancreatic cancer is the fourth leading cause of cancer death in the world. 
The aim of this study is to see level of serum bilirubin in relation to 
pancreatic cancer before and after treatment according to age and gender.  
Results presented in table and fig (1, 2, 3) indicated that there was highly 
significant difference between bilirubin level before treatment and after 
surgery and chemo-radio therapy in primary stage of pancreatic cancer. This 
indicated that the different methods of treatment lead to decrease bilirubin 
level.  But the most effective treatment was after chemo-radio therapy. This 
result was in agreement with the study of [63],[ 64], [65] who found that 
after surgery, neo adjuvant chemotherapy and radiation have been effective 
than surgery in lowering bilirubin level in pancreatic cancer. 
Result presented in table and fig (4, 5, 6) indicated that there was highly 
significant difference between bilirubin level before treatment and after 
surgery and chemo-radio therapy in advance stage of pancreatic cancer. This 
indicated that the different methods of treatment lead to decrease bilirubin 
level .But the most effective treatment was after surgery.  This result was in 
agreement with the study of [27], [7], [47], ,[58], [59], [60] who said that 
before surgery ,neo adjuvant chemo-radio therapy may used in cases are 
considered to be borderline  resectable in order to reduce the cancer to a 
level where surgery could be beneficial, the surgery more effective in this 
cases than chemo-radio therapy. The rationale for biliary decompression in 
patients with unresectable pancreatic cancer and obstructive cholestasis is 
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the normalisation of the bilirubin levels to allow palliative chemotherapy, 
and the prevention of other adverse outcomes such as cholangitis and 
frequent hospitalization
 
According to the current German, European and 
American treatment guidelines, stent placement via endoscopic retrograde 
cholangiopancreatography (ERCP) is the preferred method for biliary 
decompression in these patients.In case ERCP is not possible, percutaneous 
transhepatic biliary drainage (PTCD) is recommended ,But disagreement 
with the study of [73] who found that the chemo-radio therapy is more 
effective in borderline resectable in lowering bilirubin level.                                   
Results presented in table (7) indicated that there was significant difference 
between bilirubin level before treatment and after chemotherapy in more 
advance stage of pancreatic cancer. This result was in agreement with [27], 
[68] who said that in patients not suitable un resectable for curative surgery 
chemotherapy may be used to extend life or improve its quality on 
hyperbilirubineama . Gemcitabine was approved by the United States Food 
and Drug Administration (FDA) in 1997, after a clinical trial reported 
improvements in quality of life and a 5-week improvement in median 
survival duration in people with advanced pancreatic cancer. 
Results presented in table (8, 9, 10, 11) in appendix indicated that there was 
no significant difference between bilirubin level before and after treatment 
in pancreatic cancer  according to age and gender that  mean bilirubin level 
was not affected by gender and age. There was no previous study concerning 
the affect of gender and age on bilirubin level in patients with pancreatic 
cancer which need further conformations. This result was in agreement 
with[9],[27],[25],[12],[15],[28],[20],[29],[30] who found that there were  
many studies related the pancreatic cancer to gender  and age and with high 
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incidence of the cancer in male than female, and there was great relation 
related the bilirubin level to the patients age which appears in average over 
60.   
Result presented in table (12) in appendix indicated that was no significant 
difference between bilirubin level before treatment, after chemo-radio 
therapy and years (2015, 2016, 2017).But there was significant difference 
after surgery, after chemo therapy and years. 
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Conclusions 
1- Elevated level of serum bilirubin in pancreatic cancer patients 
(ductal adenocarcinoma) due to blockage of common bile duct by 
tumor in the head of pancreas.  
2- Effective treatment that lower bilirubin level in pancreatic cancer  
patients was after chemo-radio therapy in primary stage, after  
surgery in advance stage and after chemo therapy in more advance 
stage studied in(2015,2016,2017). 
3- level of serum bilirubin in pancreatic cancer was not affected by 
gender and age in all 3 years. 
 
Recommendations 
1. Elevated level of bilirubin may related to pancreatic cancer so can used 
serum bilirubin as marker for detection pancreatic cancer. 
2. The strongest risk factor for pancreatic cancer is increasing age. Risk is 
low in those aged between50-54 increasing sharply in those aged 75-79. 
3. The disease slightly more common in men than women. 
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Appendix 
 
Table(8): Effect of gender on total bilirubin (T.bil) level on pancreatic 
cancer patients: 
 
 
 
 
 
 
Result presented in table (8) there was no significant difference before and 
after treatment in on (T.bil) according to gender. 
 
Table ( 9) : Effect of gender on direct bilirubin (D.bil) level on pancreatic 
cancer patients: 
 
 
 
 
 
 
 
Result presented in table (9) there was no significant difference before and 
after treatment in on (D.bil) according to gender. 
 
 
 
 Mean±SD 
 
P-value 
A 
Male 12.59±3.17 
0.414 
Female 11.85±2.82 
B 
Male 2.32±0.88 
0.285 
Female 2.72±1.90 
C 
Male 2.99±1.48 
0.352 
Female 2.58±1.54 
 
 
Mean±SD P-value 
A 
Male 8.04±2.71 
0.625 
Female 7.66±2.31 
B 
Male 1.01±0.55 
0.455 
Female 1.20±1.33 
C 
Male 1.06±0.79 
0.858 
Female 1.11±0.93 
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Table ( 10) : Effect of gender on indirect bilrubin(ID.bil) level on pancreatic 
cancer patients: 
 
 
 
 
 
Result presented in table (10) there was no significant difference before and 
after treatment in on (ID.bil) according to gender. 
 
 
Mean±SD P-value 
A 
Male 4.37±1.73 
0.642 
Female 4.14±1.54 
B 
Male 1.30±0.60 
0.434 
Female 1.46±0.83 
C 
Male 1.92±0.99 
0.093 
Female 1.46±0.65 
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Table(11): Effect of age on bilirubin (bil)  level on pancreatic cancer patients 
Bilirubin mg/dl 
Age group (year) 
Mean±SD 
P. value Less than 40 40-60 More than 60 
A 
Total 16.76±1.79 14.64±0.97 15.99±1.09 0.491 
Direct  11.98±1.67 10.38±0.93 11.08±1.05 0.677 
Indirect 4.80±0.37 3.99±0.33 4.82±0.36 0.171 
B 
Total 2.11±0.18 2.84±0.34 2.17±0.17 0.121 
Direct  0.66±0.11 1.24±0.22 1.06±0.14 0.192 
Indirect 1.45±0.13 2.03±0.43 1.09±0.13 0.084 
C 
Total 2.26±0.35 3.27±0.31 2.75±0.33 0.178 
Direct  0.80±0.19 1.21±0.18 1.07±0.18 0.422 
Indirect 1.46±0.18 2.05±0.20 1.68±0.20 0.175 
D 
Total 18.09±1.96 13.28±1.51 16.20±1.55 0.172 
Direct  12.95±1.54 8.91±1.65 11.76±1.42 0.208 
Indirect 5.14±0.71 4.37±0.39 4.44±0.42 0.529 
 Result presented in table (11) there was no significant difference before 
and after treatment in bilirubin level and age. 
Table 12. Bilirubin parameters of the pancreatic patients among the study period 
Bilirubin parameters 
Study period (year) 
Overall P. value 2015 2016 2017 
A 
Total 16.12±1.51 14.55±1.11 15.91±0.98 15.62±0.68 0.679 
Direct  11.18±1.53 10.05±0.98 11.31±0.93 10.98±0.65 0.719 
Indirect 4.94±0.42 4.40±0.59 4.41±0.25 4.50±0.21 0.648 
B 
Total 3.53±0.74 2.69±0.36 2.10±0.12 2.44±0.17 0.005 
Direct  1.70±0.52 0.91±0.15 0.96±0.10 1.06±0.11 0.044 
Indirect 2.98±1.07 1.78±0.23 1.13±0.07 1.55±0.19 0.002 
C 
Total 3.22±0.46 2.89±0.43 2.79±0.26 2.88±0.20 0.752 
Direct  1.50±0.29 0.83±0.16 1.05±0.14 1.08±0.11 0.187 
Indirect 1.72±0.20 2.06±0.34 1.74±0.15 1.80±0.12 0.585 
D 
Total 10.08±1.45 13.59±1.32 19.38±1.31 15.90±0.99 0.001 
Direct  5.50±1.26 8.98±1.40 14.73±0.96 11.28±0.90 0.000 
Indirect 4.58±0.36 4.61±0.43 4.65±0.50 4.62±0.29 0.997 
Result presented in table (12) showed that there was no significant 
difference between level of bilirubin before treatment and years . But 
there was significant difference 
(P≤0.005),(P≤0.044)and(P≤0.002)respectively after surgery  between 
(T.bil) in 2015,2016 and 2017 ,in 2015  (T.bil) was3.53mg/dl ,in was 2016 
2.69mg/dl and in 2017 was 2.10mg/dl (D.bil) in 2015 was 1.70mg/dl ,In 
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2016 was (0.91)mg/dl and in 2017 was(0.96)mg/dl,(In.bil) in 2015 was 
(2.98)mg/dl, in 2016 was(1.78)mg/dl and in 2017 was(1.13)mg/dl . But 
there was no significant difference between level of bilirubin  and years  
after chemo-radio .But there was significant difference 
(P≤0.001),(P≤0.000) respectively after chemo therapy therapy between 
(T.bil) in 2015,2016 and 2017, In 2015(T.bil) was 10.08mg/dl,In 2016was 
13.59 in 2017 was 19.38mg/dl .(D.bil)was in2015 5.50 mg/dl ,in 2016 
was 8.98mg/dl and in 2017 was 14.73 mg/dl but there is no significant 
difference between level of indirect bilirubin after chemo therapy and 
years. 
 
 
